Risks of Congenital Malformations in Offspring Exposed to Valproic Acid in Utero: A Systematic Review and Cumulative Meta-analysis

Clinical Pharmacology and Therapeutics

Volumn 98, Issue 4, 2015, Pages 417-441

  Tanoshima, M ^a,b   Kobayashi, T ^a,c   Tanoshima, R ^a,b   Beyene, J ^d   Koren, G ^a   Ito, S ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b YOKOHAMA CITY UNIVERSITY HOSPITAL   (Japan)

^c NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

VALPROIC ACID; ANTICONVULSIVE AGENT;

ARTICLE; CLEFT LIP; CLEFT PALATE; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; DISEASE ASSOCIATION; FIRST TRIMESTER PREGNANCY; HUMAN; META ANALYSIS; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MUSCULOSKELETAL SYSTEM MALFORMATION; NEURAL TUBE DEFECT; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SYSTEMATIC REVIEW; UROGENITAL TRACT MALFORMATION; ABNORMALITIES, DRUG-INDUCED; ADVERSE EFFECTS; ENVIRONMENTAL EXPOSURE; FEMALE; ODDS RATIO; PREGNANCY; RISK ASSESSMENT; TIME;

ABNORMALITIES, DRUG-INDUCED; ANTICONVULSANTS; FEMALE; HUMANS; MATERNAL EXPOSURE; ODDS RATIO; PREGNANCY; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; VALPROIC ACID;

EID: 84952772212     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.158     Document Type: Article

References (33)

1. Koren, G., Nava-Ocampo, A. A., Moretti, M. E., Sussman, R. & Nulman, I. Major malformations with valproic acid. Can. Fam. Physician 52, 441-442, 444, 447 (2006).
2. Meador, K., Reynolds, M. W., Crean, S., Fahrbach, K. & Probst, C. Pregnancy outcomes in women with epilepsy: A systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res. 81, 1-13 (2008).
3. Morrow, J. I. et al. Folic acid use and major congenital malformations in offspring of women with epilepsy: A prospective study from the UK Epilepsy and pregnancy register. J. Neurol. Neurosurg. Psychiatry 80, 506-511 (2009).
4. Tomson, T. et al. Dose-dependent risk of malformations with antiepileptic drugs: An analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 10, 609-617 (2011).
5. Hernandez-Daz, S. et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology 78, 1692-1699 (2012).
6. Veiby, G., Daltveit, A. K., Engelsen, B. A. & Gilhus, N. E. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J. Neurol. 261, 579-588 (2014).
7. Campbell, E. et al. Malformation risks of antiepileptic drug monotherapies in pregnancy. J. Neurol. Neurosurg. Psychiatry 85, 1029-1034 (2014).
8. Kaaja, E., Kaaja, R. & Hiilesmaa, V. Major malformations in offspring of women with epilepsy. Neurology 60, 575-579 (2003).
9. Artama, M., Auvinen, A., Raudaskoski, T., Isojarvi, I. & Isojarvi, J. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology 64, 1874-1878 (2005).
10. Vajda, F. J. et al. Teratogenicity of the newer antiepileptic drugs-the Australian experience. J. Clin. Neurosci. 19, 57-59 (2012).
11. Samren, E. B. et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: A joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 38, 981-990 (1997).
12. Wide, K., Winbladh, B. & Kallen, B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: A nation-wide, population-based register study. Acta Paediatr. 93, 174-176 (2004).
13. Wyszynski, D. F. et al. Antiepileptic Drug Pregnancy Registry. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 64, 961-965 (2005).
14. Viinikainen, K., Heinonen, S., Eriksson, K. & Kalviainen, R. Community-based, prospective, controlled study of obstetric and neonatal outcome of 179 pregnancies in women with epilepsy. Epilepsia 47, 186-192 (2006).
15. Morrow, J. et al. Malformation risks of antiepileptic drugs in pregnancy: A prospective study from the UK Epilepsy and Pregnancy Register. J. Neurol. Neurosurg. Psychiatry 77, 193-198 (2006).
16. Vajda, F. J. et al. Foetal malformations and seizure control: 52 months data of the Australian Pregnancy Registry. Eur. J. Neurol. 13, 645-654 (2006).
17. Vajda, F. J. et al. Changing Australian prescribing patterns for antiepileptic drugs in pregnancy and their possible consequences. J. Clin. Neurosci. 14, 611-617 (2007).
18. Vajda, F. J. et al. The Australian Register of Antiepileptic Drugs in Pregnancy: The first 1002 pregnancies. Aust. N. Z. J. Obstet. Gynaecol. 47, 468-474 (2007).
19. Thomas, S. V. et al. Cardiac malformations are increased in infants of mothers with epilepsy. Pediatr. Cardiol. 29, 604-608 (2008).
20. Mart-nez, Ferri. M. et al. Malformations and fetal death in the Spanish antiepileptic drug and pregnancy registry: results at 6 years [Spanish]. Neurologia 24, 360-365 (2009).
21. Vajda, F. J. et al. Is lamotrigine a significant human teratogen Observations from the Australian Pregnancy Register. Seizure 19, 558-561 (2010).
22. Vajda, F. J. et al. The prescribing of antiepileptic drugs for pregnant Australian women. Aust. N. Z. J. Obstet. Gynaecol. 52, 49-53 (2012).
23. Kochen, S., Salera, C. & Seni, J. Pregnant women with epilepsy in a developing country. Open Neurol. J. 5, 63-67 (2012).
24. Cunnington, M. C. et al. Final results from 18 years of the International Lamotrigine Pregnancy Registry. Neurology 76, 1817-1823 (2011).
25. FDA Postmarket Drug Safety Information for Patients and Providers: risk of neural tube birth defects following prenatal exposure to valproate. . Accessed 22 February 2015.
26. DEPAKENEVR Product Monograph. . Accessed 22 February 2015.
27. Etwel, F., Hutson, J. R., Madadi, P., Gareri, J. & Koren, G. Fetal and perinatal exposure to drugs and chemicals: novel biomarkers of risk. Annu. Rev. Pharmacol. Toxicol. 54, 295-315 (2014).
28. Moher, D., Liberati, A., Tetzlaff, J. & Altman, D. G. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ 339, 332-336 (2009).
29. Stroup, D. F. et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283, 2008-2012 (2000).
30. European Surveillance of Congenital Anomalies. EUROCAT guide 1. 3 and reference documents: instructions for the registration and surveillance of congenital anomalies. . Accessed 22 February 2015.
31. Wells, G. A. et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. . Accessed 22 February 2015.
32. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 48, 452-458 (2013).
33. Sweeting, M. J., Sutton, A. J. & Lambert, P. C. What to add to nothing Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat. Med. 23, 1351-1375 (2004).